Back to Headlines
Politics
Apr 26, 2026
Analyzed by GPT OSS 120B

MPs Rally Against Wes Streeting’s New Authority Over NHS Drug Spending

AI Summary
Dozens of MPs have signed a motion condemning Health Secretary Wes Streeting’s newly granted power to direct NICE’s cost‑effectiveness threshold for NHS medicines. Critics argue the move undermines NICE’s independence, risks higher drug bills and may breach existing health legislation.

MPs Challenge New Ministerial Power Over NHS Drug Pricing

Thirty‑one MPs from Labour, the Greens, the Liberal Democrats, the SNP, Plaid Cymru and independents have signed a House of Commons motion opposing a statutory instrument that gives Wes Streeting the authority to tell the National Institute for Health and Care Excellence (NICE) which cost‑effectiveness threshold to apply when appraising new medicines.

The opposition frames the change as a “power grab” that could erode the agency’s role as an international benchmark for value‑for‑money drug decisions.

Numbers Behind the Opposition

  • 31 MPs have signed the motion.
  • The statutory instrument was issued in 2026 as part of a broader UK‑US drug‑pricing deal.
  • Health experts warn the deal could add billions of pounds to the NHS drug bill.

Potential Consequences for NHS Funding and Drug Regulation

Critics, including former health secretary Andrew Lansley, argue the new power may conflict with the Health and Social Care Act 2012, which protects NICE’s independence. If the threshold is lowered, pharmaceutical companies could secure higher prices, forcing the NHS to divert funds from other services such as surgeries or nursing staff.

Think‑tanks like the Health Foundation warn that a larger drug spend will trigger “difficult cuts” to preventative and primary‑care programmes.

What the Next Parliamentary Battles May Hold

With the motion tabled as a “prayer”—a formal way for MPs to register dissent on secondary legislation—the opposition could pressure the government to amend or repeal the instrument. John McDonnell and other senior Labour figures have signalled readiness to push for a full debate in the Commons, while the House of Lords may see a “motion of regret” from Lord Lansley.

If the government persists, legal challenges could arise over the compatibility of the statutory instrument with existing health law, potentially leading to judicial review.